S
SURGE Therapeutics
Seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed
About SURGE Therapeutics
SURGE Therapeutics is a biotechnology firm focused on improving cancer patient survival through intraoperative immunotherapy. The company has developed an injectable, biodegradable hydrogel that allows for the localized and extended release of immunotherapy drugs directly at the tumor site during surgery. This approach aims to reduce the risk of cancer recurrence by eliminating residual cancer cells left behind after surgical resection, potentially transforming the standard of care for cancer treatment.
The company's business model revolves around the development and clinical validation of its hydrogel-based drug delivery platform. SURGE Therapeutics is currently advancing its lead candidate through clinical trials, having received FDA clearance for a Phase 1/2a study in bladder cancer. The company's target market includes various types of solid tumors where surgery is a primary treatment modality. By focusing on intraoperative application, SURGE serves surgical oncologists and their patients, aiming to turn a curative-intent surgery into a more definitive treatment.
SURGE Therapeutics has secured significant funding, including a $26 million Series A financing round, to support the clinical development of its therapeutic candidates. The company's strategy involves seeking regulatory approval for its products and then commercializing them, likely through partnerships with larger pharmaceutical companies or by building its own commercial infrastructure. The ultimate goal is to establish its intraoperative immunotherapy as a new pillar of cancer care, alongside surgery, chemotherapy, and radiation.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jul 2023 | $32M | $128M | Pitango Venture Capital · Khosla Ventures · KdT Ventures · Alumni Ventures | ↗ |
| SERIES AOther financing | Oct 2022 | $26M | $104M | Pitango Venture Capital · 8VC · Cancer Research Institute · Khosla Ventures | ↗ |
Growth signals
Latest recorded traffic for SURGE Therapeutics is 1.5K monthly website visits, up 733.3% over the last three months. SURGE Therapeutics's team grew 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
SURGE Therapeutics in the Cambridge ecosystem
The SURGE Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Venture Kick
Series A10 investors entered at this stage
Khosla Ventures
Pitango Venture Capital
8VC
Cancer Research Institute
Alumni Ventures
Intuitive VC
Camford Capital
KdT Ventures
Piedmont Capital
Bioluminescence Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SURGE Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SURGE Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








